Jade Biosciences director granted 34,843 stock options

Jade Biosciences director Klein Lawrence Otto received a grant of stock options covering 34,843 shares of common stock.

Rhea-AI Filing Summary

Jade Biosciences director Klein Lawrence Otto received a grant of stock options covering 34,843 shares of common stock. These options have an exercise price of $15.22 per share and expire on June 8, 2036. The award vests in full on the earlier of June 9, 2027 or the next annual stockholder meeting, subject to his continued service. Following this compensation grant, he holds 34,843 derivative securities directly.

Insider Trade Summary

Grant/Award: 34,843 shares

Grant/Award 1 txn

Insider Klein Lawrence Otto

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	34,843	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 34,843 contracts (Direct)

Footnotes (1)

1. F1. This option represents a right to purchase shares of the Issuer's common stock, which vests in full on the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continued service to the Issuer.

Key Figures

Option grant size: 34,843 options Exercise price: $15.22 per share Underlying shares: 34,843 shares +3 more

6 metrics

Option grant size 34,843 options Stock Option (Right to Buy) granted to director

Exercise price $15.22 per share Conversion or exercise price of the options

Underlying shares 34,843 shares Common stock underlying the option award

Post-transaction holdings 34,843 derivative securities Total options held following the transaction

Expiration date June 8, 2036 Option award expiration date

Vesting date trigger Earlier of June 9, 2027 or next annual meeting Full vesting condition subject to continued service

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, vests in full, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "15.2200" per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-06-08T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vests in full financial

"This option ... vests in full on the earlier of (i) June 9, 2027"

continued service financial

"in each case, subject to the Reporting Person's continued service to the Issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Jade Biosciences (JBIO) report for Klein Lawrence Otto?

Jade Biosciences reported that director Klein Lawrence Otto received a grant of stock options. The award covers 34,843 shares of common stock as a derivative security, reflecting equity-based compensation rather than an open-market purchase of existing shares by the director.

How many Jade Biosciences (JBIO) shares are covered by the new stock option grant?

The reported stock option grant to director Klein Lawrence Otto covers 34,843 underlying shares of Jade Biosciences common stock. This entire amount is reflected as derivative securities held following the transaction, indicating his full post-grant option position in this award.

What is the exercise price of the Jade Biosciences (JBIO) stock options granted?

The stock options granted to Klein Lawrence Otto carry an exercise price of $15.22 per share. This means he can later purchase Jade Biosciences common stock at $15.22 for each of the 34,843 underlying shares covered by the award, subject to vesting.

When do Klein Lawrence Otto’s Jade Biosciences (JBIO) stock options vest?

The options vest in full on the earlier of June 9, 2027 or the date of Jade Biosciences’ next annual stockholder meeting. Vesting is conditioned on Klein Lawrence Otto’s continued service to the company through that applicable vesting date, as described in the filing footnote.

When do the newly granted Jade Biosciences (JBIO) stock options expire?

The stock options granted to Klein Lawrence Otto expire on June 8, 2036. After that expiration date, any unexercised portion of the 34,843-share option award would no longer be exercisable, effectively eliminating the right to buy stock at the $15.22 exercise price.

Did Klein Lawrence Otto buy or sell Jade Biosciences (JBIO) shares in the market?

The transaction reflects a grant of stock options classified as an acquisition under code A, not an open-market trade. It is compensation-based, giving him rights to buy 34,843 shares at $15.22, rather than a direct purchase or sale of existing Jade Biosciences shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/11/2026 - 04:41 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Klein Lawrence Otto

(Last) (First) (Middle)

C/O JADE BIOSCIENCES, INC.

221 CRESCENT ST., BLDG. 23, STE. 105

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Jade Biosciences, Inc. [ JBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$15.22	06/09/2026		A		34,843		(1)	06/08/2036	Common Stock	34,843	$0	34,843	D

Explanation of Responses:

1. This option represents a right to purchase shares of the Issuer's common stock, which vests in full on the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continued service to the Issuer.

	/s/ Elizabeth Balta, as attorney-in-fact for Lawrence Otto Klein	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)